Class 2 Medicines : Norgine Pharmaceuticals Limited, Pedmarqsi 80
OFFICIAL-SOURCE RECALL · UNITED KINGDOM
Class 4 Medicines Defect Notification: Macarthys Laboratories Ltd Recall: Macarthys Laboratories Ltd T/A
Use the identifiers printed on your item to determine whether this recall may affect the product you own.
CountryUnited KingdomPublishedJuly 20, 2026Last updatedJuly 20, 2026Official source last checkedSeptember 9, 2026 at 1:48 PM UTC
CHECK THE ITEM YOU OWN
Is your product affected?
- Brand
- See official notice
- Product
- Class 4 Medicines Defect Notification: Macarthys Laboratories Ltd T/A Martindale Pharma, Xaggitin XL Prolonged-release Tablets, EL(26)A/35
- Manufacturer
- See official notice
The barcode may identify the product type, while the recall may apply only to certain lots, dates or variants. Check all identifiers listed in the official recall.
Why this product was recalled
Macarthys Laboratories Ltd T/A Martindale Pharma has notified the MHRA of a manufacturing issue impacting several batches of Xaggitin XL Prolonged-release Tablets, due to the occurrence of incorrect tablet counts in the bottles.
Hazard
Macarthys Laboratories Ltd T/A Martindale Pharma has notified the MHRA of a manufacturing issue impacting several batches of Xaggitin XL Prolonged-release Tablets, due to the occurrence of incorrect tablet counts in the bottles.
What consumers should do
for Healthcare Professionals: Please physically check the quantity of tablets when receiving the packs and when dispensing these tablets, this may include breaking the tamper evident seal. Please report any affected packs to licensed@ethypharm.com using the reference Ethypharm supply for any reconciliation excursions experienced due to this defect. Be aware that patients may return for their next prescription earlier than expected. Advice for Patients: Patients should be aware that some packs of the affected batches may have an incorrect number of tablets in the bottle, leading to missing or additional tablets. Patients may continue to take the tablets prescribed by your doctor as the quality of the tablets is not impacted by this defect. Patients who experience adverse reactions or have any questions about their medication should seek medical attention. Any suspected adverse reactions should also be reported via the MHRA Yellow Card scheme . Additional information: For all medical information enquiries and information on this product, please email medinfo@ethypharm.com or telephone 01277 266 600 Selecting Option 2. For stock control enquiries please email licensed@ethypharm.com ,
Official recall notice
Class 4 Medicines Defect Notification: Macarthys Laboratories Ltd T/A Martindale Pharma, Xaggitin XL Prolonged-release Tablets, EL(26)A/35
Agency: Medicines and Healthcare products Regulatory Agency
Official publication date: July 20, 2026
Read the official UK_MHRA recall notice →SCAN ONCE. KEEP WATCHING.
Keep an eye on the products at home.
Scan food and household product barcodes, save your items and get notified when a future recall may match.
